Stock Analysis

View All
PANW daily stock chart with 10, 20, 50, 150 and 200-day moving averages, volume and RS line versus SPY, Stage 2 (Advancing), as of August 31, 2026 at 01:14 — CANSLIM Research

PANW Stage 2 Uptrend Intact; Bull Flag Setup Near 396 Pivot

Palo Alto Networks (PANW) is trading in a Stage 2 advancing trend, holding above a…

Read More
NIO daily stock chart with 10, 20, 50, 150 and 200-day moving averages, volume and RS line versus SPY, Stage 3→4 (Topping / Early Decline), as of August 31, 2026 at 01:13 — CANSLIM Research

NIO Breaks Below 30-Week MA as Stage 3→4 Topping Signals Distribution Risk

NIO is exhibiting a Stage 3 to Stage 4 transition, with the 30-week moving average…

Read More
MDT daily stock chart with 10, 20, 50, 150 and 200-day moving averages, volume and RS line versus SPY, Stage 3 (Topping), as of August 31, 2026 at 01:12 — CANSLIM Research

MDT forms Cup with Handle near pivot; Stage 3 topping keeps sentiment neutral

Medtronic (MDT) is tracing a 38-week Cup with Handle base, with the handle currently resolving…

Read More

WDAY Earnings: EPS Beat Signals Stage 4 Decline

Westday (WDAY) delivered a robust quarterly performance, reporting earnings per share of $2.75 against a consensus estimate of $2.61, representing a positive surprise of 5.27%. This beat was underpinned by revenue growth of 13.48% year-on-year, driven largely by the company’s strategic pivot towards enterprise-focused AI solutions and enhanced cloud infrastructure services. While the fundamental numbers demonstrate operational resilience and effective cost management, the market reaction suggests that investors are increasingly pricing in near-term headwinds despite the short-term earnings uplift.

TD Bank Earnings: Strong Beat Signals Stage 2 Momentum

TD Bank reported third-quarter results that significantly outperformed Wall Street expectations, with earnings per share rising to $2.77 against a consensus of $2.47. This substantial surprise reflects effective cost management and favourable deposit behaviour across the UK and US markets, while revenue grew by nearly 6% year-on-year, demonstrating resilience in a volatile interest rate environment.

CM Earnings: 8.2% Beat Signals Strong Growth Momentum

Citi-Metro (CM) has exceeded Wall Street expectations with reported earnings of $2.73 per share, significantly outperforming the consensus estimate of $2.52 and delivering an 8.2% positive surprise. Revenue growth remains a key driver, posting year-on-year expansion of approximately 14%, which underscores the company’s ability to maintain pricing power and operational efficiency despite macroeconomic headwinds. This performance suggests that management’s strategic focus on cost optimisation and market share acquisition is yielding tangible results, reinforcing investor confidence in the business model.

BURL Earnings: Massive EPS Beat Signals Consolidation Phase

Burlington Stores (BURL) has exceeded Wall Street expectations with reported earnings per share of $2.96, significantly outperforming the consensus estimate of $2.19. This represents a robust 35.4% surprise, underpinned by year-over-year revenue growth of 14.1%. The company’s operational resilience is evident in its ability to maintain margins despite broader market headwinds, with same-store sales providing a solid foundation for the full-year performance.

BILI Earnings: EPS Beat But Bearish Technicals Signal Decline

BILI announced earnings of $1.58 per share, edging above the analyst consensus of $1.53 and delivering a positive surprise of approximately three per cent. Revenue growth remained modest at 6.7% year-on-year, reflecting continued headwinds in the domestic market despite operational efficiencies. While the bottom-line result suggests some stabilisation in cost management, the lack of significant top-line acceleration indicates that organic demand is struggling to recover from recent regulatory and competitive pressures.

LTRX Earnings: In-Line EPS Misses Expectations Amid Declining Stage

Luminex Corporation reported fiscal earnings that met analyst expectations, with net income per share reaching $0.04 against a consensus estimate of the same figure. This represents a modest positive surprise of 4.36%, though it fails to demonstrate the robust growth required to reverse current market sentiment. Revenue grew by 5.9% year-on-year, driven primarily by continued demand for its proprietary DNA sequencing platforms and expanded service offerings in clinical diagnostics. However, the lack of significant margin expansion or accelerated top-line growth suggests that operational momentum remains subdued despite the headline figures.